DOCSLIB.ORG

Role of Nuclear Metabotropic Glutamate Receptor 5 in Rat Models of Persistent Pain

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Role of Nuclear Metabotropic Glutamate Receptor 5 in Rat Models of Persistent Pain Role of nuclear metabotropic glutamate receptor 5 in rat models of persistent pain Kathleen Vincent Department of Psychology Faculty of Science McGill University Montreal, Quebec, Canada December 2017 A thesis submitted to McGill University Faculty of Graduate and Postdoctoral Studies Office in partial fulfillment for the degree of Doctor of Philosophy in the Department of Psychology © Kathleen Vincent, 2017 i Table of Contents Table of Figures ............................................................................................................................................ v Abbreviations ............................................................................................................................................. vii Abstract ....................................................................................................................................................... xi Résumé...................................................................................................................................................... xiii Acknowledgements .................................................................................................................................... xv Contributions of authors .......................................................................................................................... xvii Introduction ................................................................................................................................................ 1 Background .............................................................................................................................................. 1 Metabotropic glutamate receptor structure and subtypes .................................................................... 3 Group I mGluR splice variants ............................................................................................................. 4 Group I mGluR-linked intracellular messengers ..................................................................................... 5 DAG-mediated signalling pathway ...................................................................................................... 7 IP3-mediated signalling pathway ......................................................................................................... 8 JNK pathway ........................................................................................................................................ 8 G protein-mediated calcium oscillations ............................................................................................. 9 G protein-independent signalling ...................................................................................................... 10 Group I mGluR scaffolding interactions ................................................................................................ 11 Group I mGluR agonists ......................................................................................................................... 13 mGluR5 antagonists and inverse agonists ............................................................................................ 16 Localization of mGluRs in the SCDH ...................................................................................................... 20 Expression and regulation of mGluR5 following injury ......................................................................... 21 Intracellular GPCRs ................................................................................................................................ 23 Nuclear mGluR5 .................................................................................................................................... 25 Activating nuclear mGluR5 .................................................................................................................... 27 Excitatory amino acid transporters ................................................................................................... 27 Membrane permeability .................................................................................................................... 30 Nuclear mGluR5 implications for pain .................................................................................................. 31 Involvement of EAATs in pain ............................................................................................................... 33 EAAT inhibitors: Development and subtype selectivity .................................................................... 33 ii EAAT inhibitors and nociception ....................................................................................................... 35 EAAT expression following injury ...................................................................................................... 35 EAATs inhibitors in animals with persistent pain .............................................................................. 37 Background on methodologies selected ............................................................................................... 42 Animal models of neuropathic pain .................................................................................................. 42 Animal models of inflammatory pain ................................................................................................ 45 Testing methods for assessing pain hypersensitivity ........................................................................ 48 Methods .................................................................................................................................................... 53 Animals .................................................................................................................................................. 53 Neuropathic model: Spared nerve injury (SNI) ..................................................................................... 54 Inflammatory model: Complete Freund’s adjuvant (CFA) .................................................................... 55 Materials ............................................................................................................................................... 56 Drug administration .............................................................................................................................. 56 Nociceptive testing ................................................................................................................................ 57 Glutamate-induced pain behaviors ................................................................................................... 57 Mechanical allodynia testing ............................................................................................................. 57 Conditioned place preference – SNI .................................................................................................. 58 Conditioned place preference – CFA ................................................................................................. 59 Immunohistochemistry ......................................................................................................................... 60 Tissue preparation ............................................................................................................................. 60 Staining protocol................................................................................................................................ 60 Cell counting ...................................................................................................................................... 61 Subcellular fractionation and western blot analysis ............................................................................. 62 Tissue collection ................................................................................................................................ 62 Western blot ...................................................................................................................................... 63 Microdialysis Sampling .......................................................................................................................... 64 Statistical analysis.................................................................................................................................. 64 Results ....................................................................................................................................................... 67 mGluR5 is increased in nuclear-enriched SCDH fractions of rats with neuropathic pain .................... 67 mGluR5 is increased in nuclear-enriched SCDH fractions of rats with inflammatory pain .................. 70 Nuclear mGluR5 increased by one day following SNI surgery .............................................................. 74 iii Nuclear mGluR5 increased by one day following CFA injection ........................................................... 76 Spinal glutamate induces pain behaviors in rats .................................................................................. 79 Glutamate induces greater Fos expression in the SCDH of rats with persistent pain .......................... 82 Glutamate induces greater Jun expression in the SCDH of rats with persistent pain .......................... 84 Blocking neuronal glutamate uptake is antinociceptive in animals with neuropathic pain ................. 86 Blocking
Load more

Recommended publications
  • Mglur5 Modulation As a Treatment for Parkinson's Disease
    mGluR5 modulation as a treatment for Parkinson’s disease Kyle Farmer A thesis submitted to the Faculty of Graduate & Postdoctoral Affairs in partial fulfillment of requirements of the degree of Doctor of Philosophy in Neuroscience Carleton University Ottawa, ON Copyright © 2018 – Kyle Farmer ii Space Abstract Parkinson’s disease is an age related neurodegenerative disease. Current treatments do not reverse the degenerative course; rather they merely manage symptom severity. As such there is an urgent need to develop novel neuroprotective therapeutics. There is an additional need to stimulate and promote inherent neuro-recovery processes. Such processes could maximize the utilization of the existing dopamine neurons, and/or recruit alternate neuronal pathways to promote recovery. This thesis investigates the therapeutic potential of the mGluR5 negative allosteric modulator CTEP in a 6-hydroxydopamine mouse model of Parkinson’s disease. We found that CTEP caused a modest reduction in the parkinsonian phenotype after only 1 week of treatment. When administered for 12 weeks, CTEP was able to completely reverse any parkinsonian behaviours and resulted in full dopaminergic striatal terminal re-innervation. Furthermore, restoration of the striatal terminals resulted in normalization of hyperactive neurons in both the striatum and the motor cortex. The beneficial effects within the striatum iii were associated with an increase in activation of mTOR and p70s6K activity. Accordingly, the beneficial effects of CTEP can be blocked if co-administered with the mTOR complex 1 inhibitor, rapamycin. In contrast, CTEP had differential effects in the motor cortex, promoting ERK1/2 and CaMKIIα instead of mTOR. Together these data suggest that modulating mGluR5 with CTEP may have clinical significance in treating Parkinson’s disease.
    [Show full text]
  • Metabotropic Glutamate Receptors
    mGluR Metabotropic glutamate receptors mGluR (metabotropic glutamate receptor) is a type of glutamate receptor that are active through an indirect metabotropic process. They are members of thegroup C family of G-protein-coupled receptors, or GPCRs. Like all glutamate receptors, mGluRs bind with glutamate, an amino acid that functions as an excitatoryneurotransmitter. The mGluRs perform a variety of functions in the central and peripheral nervous systems: mGluRs are involved in learning, memory, anxiety, and the perception of pain. mGluRs are found in pre- and postsynaptic neurons in synapses of the hippocampus, cerebellum, and the cerebral cortex, as well as other parts of the brain and in peripheral tissues. Eight different types of mGluRs, labeled mGluR1 to mGluR8, are divided into groups I, II, and III. Receptor types are grouped based on receptor structure and physiological activity. www.MedChemExpress.com 1 mGluR Agonists, Antagonists, Inhibitors, Modulators & Activators (-)-Camphoric acid (1R,2S)-VU0155041 Cat. No.: HY-122808 Cat. No.: HY-14417A (-)-Camphoric acid is the less active enantiomer (1R,2S)-VU0155041, Cis regioisomer of VU0155041, is of Camphoric acid. Camphoric acid stimulates a partial mGluR4 agonist with an EC50 of 2.35 osteoblast differentiation and induces μM. glutamate receptor expression. Camphoric acid also significantly induced the activation of NF-κB and AP-1. Purity: ≥98.0% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg (2R,4R)-APDC (R)-ADX-47273 Cat. No.: HY-102091 Cat. No.: HY-13058B (2R,4R)-APDC is a selective group II metabotropic (R)-ADX-47273 is a potent mGluR5 positive glutamate receptors (mGluRs) agonist.
    [Show full text]
  • Mglur5 Activity Moderates Vulnerability to Chronic Social Stress
    Neuropsychopharmacology (2015) 40, 1222–1233 & 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org Homer1/mGluR5 Activity Moderates Vulnerability to Chronic Social Stress 1 1 1 1 1 Klaus V Wagner , Jakob Hartmann , Christiana Labermaier , Alexander S Ha¨usl , Gengjing Zhao , 1 1 2 1 1 1 Daniela Harbich , Bianca Schmid , Xiao-Dong Wang , Sara Santarelli , Christine Kohl , Nils C Gassen , 3,4 1 1 1 5 Natalie Matosin , Marcel Schieven , Christian Webhofer , Christoph W Turck , Lothar Lindemann , 6 5 1 1 ,1 Georg Jaschke , Joseph G Wettstein , Theo Rein , Marianne B Mu¨ller and Mathias V Schmidt* 1 2 Department of Stress Neurobiology and Neurogenetics, Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurobiology, Key Laboratory of Medical Neurobiology of Ministry of Health of China, Zhejiang Province Key Laboratory of Neurobiology, Zhejiang University 3 School of Medicine, Hangzhou, China; Faculty of Science, Medicine and Health and Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW, Australia; 4Schizophrenia Research Institute, Sydney NSW, Australia; 5Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology, and Rare Diseases Translational Area (NORD), Basel, Switzerland; 6Roche Pharmaceutical Research and Early Development, Discovery Chemistry, Basel, Switzerland Stress-induced psychiatric disorders, such as depression, have recently been linked to changes in glutamate transmission in the central nervous system. Glutamate signaling is mediated by a range of receptors, including metabotropic glutamate receptors (mGluRs). In particular, mGluR subtype 5 (mGluR5) is highly implicated in stress-induced psychopathology. The major scaffold protein Homer1 critically interacts with mGluR5 and has also been linked to several psychopathologies.
    [Show full text]
  • Aβ Oligomers Induce Sex-Selective Differences in Mglur5 Pharmacology and Pathophysiological Signaling in Alzheimer Mice
    bioRxiv preprint doi: https://doi.org/10.1101/803262; this version posted June 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. TITLE: Aβ oligomers induce sex-selective differences in mGluR5 pharmacology and pathophysiological signaling in Alzheimer mice Khaled S. Abd-Elrahman1,2,6,#, Awatif Albaker1,2,7,#, Jessica M. de Souza1,2,8, Fabiola M. Ribeiro8, Michael G. Schlossmacher1,2,3,5, Mario Tiberi1,2,4,5, Alison Hamilton1,2,$ and Stephen S. G. Ferguson1,2,$,* 1University of Ottawa Brain and Mind Institute, 2Departments of Cellular and Molecular Medicine, 3 Medicine, 4Psychiatry, and the 5Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, K1H 8M5, Canada. 6Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt. 7Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 12371, Saudi Arabia 8Department of Biochemistry and Immunology, ICB, Universidade Federalde Minas Gerais, Belo Horizonte, Brazil. #These authors contributed equally $ Co-senior authors ONE-SENTENCE SUMMARY: Aβ/PrPC complex binds to mGluR5 and activates its pathological signaling in male, but not female brain and therefore, mGluR5 does not contribute to the pathology in female Alzheimer’s mice. *Corresponding author Dr. Stephen S. G. Ferguson Department of Cellular and Molecular Medicine, University of Ottawa, 451 Smyth Dr. Ottawa, Ontario, Canada, K1H 8M5. Tel: (613) 562 5800 Ext 8889. [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/803262; this version posted June 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Glutamatergic Regulation of Cognition and Functional Brain Connectivity: Insights from Pharmacological, Genetic and Translational Schizophrenia Research
    Title: Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research Authors: Dr Maria R Dauvermann (1,2) , Dr Graham Lee (2) , Dr Neil Dawson (3) Affiliations: 1. School of Psychology, National University of Ireland, Galway, Galway, Ireland 2. McGovern Institute for Brain Research, Massachusetts Institute of Technology, 77 Massachusetts Ave, Cambridge, MA, 02139, USA 3. Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, LA1 4YQ, UK Abstract The pharmacological modulation of glutamatergic neurotransmission to improve cognitive function has been a focus of intensive research, particularly in relation to the cognitive deficits seen in schizophrenia. Despite this effort there has been little success in the clinical use of glutamatergic compounds as procognitive drugs. Here we review a selection of the drugs used to modulate glutamatergic signalling and how they impact on cognitive function in rodents and humans. We highlight how glutamatergic dysfunction, and NMDA receptor hypofunction in particular, is a key mechanism contributing to the cognitive deficits observed in schizophrenia, and outline some of the glutamatergic targets that have been tested as putative procognitive targets for the disorder. Using translational research in this area as a leading exemplar, namely models of NMDA receptor hypofunction, we discuss how the study of functional brain network connectivity can provide new insight
    [Show full text]
  • Development of Allosteric Modulators of Gpcrs for Treatment of CNS Disorders Hilary Highfield Nickols A, P
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Neurobiology of Disease 61 (2014) 55–71 Contents lists available at ScienceDirect Neurobiology of Disease journal homepage: www.elsevier.com/locate/ynbdi Review Development of allosteric modulators of GPCRs for treatment of CNS disorders Hilary Highfield Nickols a, P. Jeffrey Conn b,⁎ a Division of Neuropathology, Department of Pathology, Microbiology and Immunology, Vanderbilt University, USA b Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA article info abstract Article history: The discovery of allosteric modulators of G protein-coupled receptors (GPCRs) provides a promising new strategy Received 25 July 2013 with potential for developing novel treatments for a variety of central nervous system (CNS) disorders. Tradition- Revised 13 September 2013 al drug discovery efforts targeting GPCRs have focused on developing ligands for orthosteric sites which bind en- Accepted 17 September 2013 dogenous ligands. Allosteric modulators target a site separate from the orthosteric site to modulate receptor Available online 27 September 2013 function. These allosteric agents can either potentiate (positive allosteric modulator, PAM) or inhibit (negative allosteric modulator, NAM) the receptor response and often provide much greater subtype selectivity than Keywords: Allosteric modulator orthosteric ligands for the same receptors. Experimental evidence has revealed more nuanced pharmacological CNS modes of action of allosteric modulators, with some PAMs showing allosteric agonism in combination with pos- Drug discovery itive allosteric modulation in response to endogenous ligand (ago-potentiators) as well as “bitopic” ligands that GPCR interact with both the allosteric and orthosteric sites. Drugs targeting the allosteric site allow for increased drug Metabotropic glutamate receptor selectivity and potentially decreased adverse side effects.
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • Dissecting the Signaling Pathways Involved in the Crosstalk Between
    Molecular Pharmacology Fast Forward. Published on June 23, 2016 as DOI: 10.1124/mol.116.104372 This article has not been copyedited and formatted. The final version may differ from this version. MOL #104372 Dissecting the signaling pathways involved in the crosstalk between mGlu5 and CB1 receptors Downloaded from Isabella G. Olmo, Talita H. Ferreira-Vieira and Fabiola M. Ribeiro molpharm.aspetjournals.org Department of Biochemistry and Immunology, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 31270-901: IGO, THV and FMR. at ASPET Journals on September 26, 2021 1 Molecular Pharmacology Fast Forward. Published on June 23, 2016 as DOI: 10.1124/mol.116.104372 This article has not been copyedited and formatted. The final version may differ from this version. MOL #104372 Running title page Running title: mGlu5/CB1 cell signaling crosstalk Corresponding author: Dr. Fabiola M. Ribeiro, Departamento de Bioquimica e Imunologia, ICB, Universidade Federal de Minas Gerais, Ave. Pres. Antonio Carlos 6627, Belo Horizonte, MG, Brazil, CEP: 31270-901, Tel.: 55-31-3409-2655; Downloaded from [email protected] Co-corresponding author: Dr. Talita H. Ferreira-Vieira, Departamento de Bioquimica e molpharm.aspetjournals.org Imunologia, ICB, Universidade Federal de Minas Gerais, Ave. Pres. Antonio Carlos 6627, Belo Horizonte, MG, Brazil, CEP: 31270-901, Tel.: 55-31-3409-3022; [email protected] at ASPET Journals on September 26, 2021 Additional informations: Number of text pages - 17 Number of tables – 2 Number of figures – 3 Number of references – 164 Number of words in abstract - 110 Number of words in the text - 4161 2 Molecular Pharmacology Fast Forward.
    [Show full text]
  • Blocking Metabotropic Glutamate Receptor Subtype 5 Relieves Maladaptive Chronic Stress Consequences
    Brain, Behavior, and Immunity 59 (2017) 79–92 Contents lists available at ScienceDirect Brain, Behavior, and Immunity journal homepage: www.elsevier.com/locate/ybrbi Full-length Article Blocking metabotropic glutamate receptor subtype 5 relieves maladaptive chronic stress consequences Daniel Peterlik a, Christina Stangl a, Amelie Bauer a, Anna Bludau a, Jana Keller a, Dominik Grabski a, Tobias Killian a, Dominic Schmidt b, Franziska Zajicek a, Georg Jaeschke d, Lothar Lindemann c, ⇑ ⇑ Stefan O. Reber e, Peter J. Flor a, , Nicole Uschold-Schmidt a, a Faculty of Biology and Preclinical Medicine, Laboratory of Molecular and Cellular Neurobiology, University of Regensburg, D-93053 Regensburg, Germany b Institute of Immunology, University of Regensburg, D-93042 Regensburg, Germany c Roche Pharmaceutical Research and Early Development, Discovery Neuroscience, Neuroscience, Ophthalmology, and Rare Diseases, Roche Innovation Center Basel, CH-4070 Basel, Switzerland d Roche Pharmaceutical Research and Early Development, Discovery Chemistry, Roche Innovation Center Basel, CH-4070 Basel, Switzerland e Laboratory for Molecular Psychosomatics, Clinic for Psychosomatic Medicine and Psychotherapy, University of Ulm, D-89081 Ulm, Germany article info abstract Article history: Etiology and pharmacotherapy of stress-related psychiatric conditions and somatoform disorders are Received 24 March 2016 areas of high unmet medical need. Stressors holding chronic plus psychosocial components thereby bear Received in revised form 29 July 2016 the highest health
    [Show full text]
  • Group I Metabotropic Glutamate Receptor Mediated Dynamic Immune
    Careaga et al. Journal of Neuroinflammation 2014, 11:110 JOURNAL OF http://www.jneuroinflammation.com/content/11/1/110 NEUROINFLAMMATION RESEARCH Open Access Group I metabotropic glutamate receptor mediated dynamic immune dysfunction in children with fragile X syndrome Milo Careaga1,2, Tamanna Noyon2, Kirin Basuta3, Judy Van de Water2,4, Flora Tassone2,3, Randi J Hagerman2,5 and Paul Ashwood1,2* Abstract Background: Fragile X syndrome (FXS) is the leading cause of inheritable intellectual disability in male children, and is predominantly caused by a single gene mutation resulting in expanded trinucleotide CGG-repeats within the 5’ untranslated region of the fragile X mental retardation (FMR1) gene. Reports have suggested the presence of immune dysregulation in FXS with evidence of altered plasma cytokine levels; however, no studies have directly assessed functional cellular immune responses in children with FXS. In order to ascertain if immune dysregulation is present in children with FXS, dynamic cellular responses to immune stimulation were examined. Methods: Peripheral blood mononuclear cells (PBMC) were from male children with FXS (n = 27) and from male aged-matched typically developing (TD) controls (n = 8). PBMC were cultured for 48 hours in media alone or with lipopolysaccharides (LPS; 1 μg/mL) to stimulate the innate immune response or with phytohemagglutinin (PHA; 8 μg/mL) to stimulate the adaptive T-cell response. Additionally, the group I mGluR agonist, DHPG, was added to cultures to ascertain the role of mGluR signaling in the immune response in subject with FXS. Supernatants were harvested and cytokine levels were assessed using Luminex multiplexing technology. Results: Children with FXS displayed similar innate immune response following challenge with LPS alone when compared with TD controls; however, when LPS was added in the presence of a group I mGluR agonist, DHPG, increased immune response were observed in children with FXS for a number of pro-inflammatory cytokines including IL-6 (P = 0.02), and IL-12p40 (P < 0.01).
    [Show full text]
  • Metabotropic Glutamate Receptors Molecular Pharmacology
    Tocris Scientific Review Series Tocri-lu-2945 Metabotropic Glutamate Receptors Molecular Pharmacology Francine C Acher Introduction Laboratoire de Chimie et Biochimie Pharmacologiques et Glutamate is the major excitatory neurotransmitter in the brain. It Toxicologiques, UMR8601-CNRS, Université René Descartes- is released from presynaptic vesicles and activates postsynaptic Paris V, 45 rue des Saints-Pères, 75270 Paris Cedex 06, France. ligand-gated ion channel receptors (NMDA, AMPA and kainate E-mail: [email protected] receptors) to secure fast synaptic transmission.1 Glutamate also activates metabotropic glutamate (mGlu) receptors which Francine C Acher is currently a CNRS Research Director within modulate its release and postsynaptic response as well as the the Biomedical Institute of University Paris-V (France). Her activity of other synapses.2,3 Glutamate has been shown to be research focuses on structure/function studies and drug involved in many neuropathologies such as anxiety, pain, discovery using chemical tools (synthetic chemistry, molecular ischemia, Parkinson’s disease, epilepsy and schizophrenia. modeling), molecular biology and pharmacology within Thus, because of their modulating properties, mGlu receptors interdisciplinary collaborations. are recognized as promising therapeutic targets.3,4 It is expected that drugs acting at mGlu receptors will regulate the glutamatergic system without affecting the normal synaptic transmission. mGlu receptors are G-protein coupled receptors (GPCRs). Eight subtypes have been
    [Show full text]
  • Metabotropic Glutamate Receptors Review
    Metabotropic Glutamate Receptors Molecular Pharmacology Francine C. Acher Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR8601‑CNRS, Université Paris Descartes, 45 rue des Saints‑Pères, 75270 Paris Cedex 06, France. E‑mail: [email protected] Francine C. Acher is currently a CNRS Research Director within the Biomedical Institute of University Paris Descartes (France). Her research focuses on structure/function studies and drug discovery using chemical tools (synthetic chemistry, molecular modeling), molecular biology and pharmacology within interdisciplinary collaborations. Contents Figure 1 | Classification of the Subtypes of Introduction ........................................................................ 1 mGlu Receptors Competitive Ligands ......................................................... 2 Sequence identity Group Transduction Agonists .......................................................................... 4 40 50 60 70 80 90% Group I ....................................................................... 5 | | | | | | Group II ...................................................................... 5 mGlu1 Group III ..................................................................... 5 I Gq +PLC mGlu5 Antagonists ..................................................................... 6 mGlu Group I ....................................................................... 6 2 II Gi/Go ‑AC Group II ...................................................................... 7 mGlu3 Group
    [Show full text]